VaxigripTetra (Quadrivalent Influenza Vaccine) – evidence for clinical and economic benefits from vaccination in population aged 65 and over in Poland
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2017, Vol 2, Issue 2
Abstract
Background: Vaccination is considered to be the most effective way of preventing influenza related-illnesses and their complications, which is particularly important in elderly population (aged 65+), often characterized with more rapid and severe clinical course of infection. Quadrivalent influenza vaccines (QIV) have been developed to avoid the poor antigenic match observed in the trivalent formulation vaccine (TIV). Methods: The study assess the immunogenicity, cost-effectiveness and impact on the Polish budget of inactivated quadrivalent influenza vaccine (VaxigripTetra), assuming its reimbursement in the active immunization of adults 65 years of age and older. Results: As clinical results have shown, non-inferior immunogenicity of QIV to each TIV for the shared strains and superior immunogenicity of QIV to each TIV for the alternate B strain. The inactivated QIV was well tolerated. VaxigripTetra is a highly cost-effective option compared to the strategy of “no vaccination” (ICUR=14,988 PLN/QALY – payer’s + patients’ perspective [PPP+P], ICUR=6,838 PLN/QALY – payers’ perspective [PPP]) and also to TIV (ICUR=121,418 PLN or ICUR=114,360 PLN, respectively). The increase of the public payer’s expenditures – 9.0-23.3 million PLN annually – will result in additional health effects: 1,091 – 4,805 GP visits, 175-771 hospitalizations and 74-326 deaths avoided per year. Conclusions: VaxigripTetra reimbursement could trigger a faster switch from TIVs to QIVs and at the same time could increase the vaccine coverage of the elderly population in Poland, which would lessen the ILI-related negative impact on that population at a reasonable cost to the healthcare system, while providing some savings to society.
Authors and Affiliations
Łukasz Kaczyński, Dariusz Pawlik, Beata Serafin, Rafał Wójcik, Marcin Kaczor, Joanna Lis, Ewelina Bernaszuk, Katarzyna Wepsięć
Keywords
Related Articles
- EP ID EP326192
- DOI 10.7365/JHPOR.2017.2.3
- Views 74
- Downloads 0
Treatment and prevention of bleeding in adult hemophilia A patients with inhibitor – economic analysis.
Hemophilia A is caused by an absence or deficiency of coagulation factor VIII. Patients with hemophilia may experience recurrent spontaneous hemarthroses or internal bleeding. Following the treatment with factor VIII con...
Mepolizumab: a new drug programme for patients with severe eosinophilic asthma
Biological treatment involves more and more fields of medicine. This also applies to severe asthma for which a therapy with omalizumab (anti-IgE antibodies for patients with allergic asthma) has been available since 2013...
Protection of sensitive data in telemedicine services
The article presents security risks related to the use of telemedicine services and technical guidelines for protection of the medical records in terms of their confidentiality, integrity and availability. It also mentio...
The access to an ophthalmic treatment in Poland on the example of the ocular complications in the course of diabetes mellitus
Background Diabetic Retinopathy (DR) is the severe disease, that develops as a result of diabetes complication. All diabetic patients are at risk of DR development and the National Health Fund (NHF) estimates that ther...
Is the cost-effectiveness threshold cost-effective in cancer therapy?
Introduction: To compare availability of innovative cancer drugs in countries with established cost-effectiveness threshold (Great Britain, Czech Republic, Sweden and Poland) and where this criterion is not used (Germany...